Tamar Securities LLC Acquires 2,211 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tamar Securities LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,492 shares of the biopharmaceutical company’s stock after buying an additional 2,211 shares during the period. Regeneron Pharmaceuticals comprises about 2.3% of Tamar Securities LLC’s investment portfolio, making the stock its 24th largest holding. Tamar Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $16,286,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of REGN. Global Assets Advisory LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth about $339,594,000. Capital International Investors boosted its position in shares of Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after buying an additional 184,561 shares during the period. TD Asset Management Inc boosted its position in shares of Regeneron Pharmaceuticals by 162.9% during the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock worth $259,402,000 after buying an additional 166,998 shares during the period. Finally, Swedbank AB acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth about $129,257,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.8 %

Shares of REGN opened at $1,007.96 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The business’s fifty day moving average is $1,114.69 and its 200-day moving average is $1,039.93. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The firm has a market cap of $111.06 billion, a price-to-earnings ratio of 29.78, a PEG ratio of 3.45 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter last year, the company posted $8.79 EPS. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.82 EPS for the current fiscal year.

Analysts Set New Price Targets

REGN has been the subject of several recent research reports. Leerink Partners reissued a “market perform” rating and set a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Royal Bank of Canada increased their price target on Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. Canaccord Genuity Group reissued a “buy” rating and set a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Wells Fargo & Company reissued an “overweight” rating and set a $1,200.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, September 23rd. Finally, Piper Sandler upped their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,116.00.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.